UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $65.08 Million Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 11.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 892,686 shares of the company’s stock after selling 114,421 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Henry Schein were worth $65,077,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cromwell Holdings LLC lifted its position in Henry Schein by 93.4% in the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock valued at $26,000 after acquiring an additional 170 shares in the last quarter. Studio Investment Management LLC grew its holdings in shares of Henry Schein by 3.8% during the third quarter. Studio Investment Management LLC now owns 4,674 shares of the company’s stock worth $341,000 after buying an additional 172 shares in the last quarter. Simplify Asset Management Inc. grew its holdings in shares of Henry Schein by 5.0% during the second quarter. Simplify Asset Management Inc. now owns 3,695 shares of the company’s stock worth $237,000 after buying an additional 175 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in Henry Schein by 3.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 5,680 shares of the company’s stock valued at $364,000 after acquiring an additional 176 shares in the last quarter. Finally, Mather Group LLC. lifted its stake in Henry Schein by 16.8% in the 2nd quarter. Mather Group LLC. now owns 1,502 shares of the company’s stock valued at $96,000 after acquiring an additional 216 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Evercore ISI lifted their price target on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Barrington Research restated an “outperform” rating and set a $82.00 price objective on shares of Henry Schein in a research note on Wednesday, November 6th. UBS Group lowered their target price on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Finally, Robert W. Baird reduced their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Six research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Henry Schein has an average rating of “Moderate Buy” and a consensus price target of $79.38.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $76.50 on Tuesday. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average price is $71.57 and its two-hundred day moving average price is $69.88. The company has a market cap of $9.54 billion, a PE ratio of 31.48, a price-to-earnings-growth ratio of 2.21 and a beta of 0.87. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.63.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.05. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s revenue was up .4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.32 EPS. On average, analysts predict that Henry Schein, Inc. will post 4.78 EPS for the current year.

Insider Activity at Henry Schein

In other news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the sale, the senior vice president now directly owns 71,833 shares in the company, valued at approximately $4,978,026.90. This represents a 22.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Michael S. Ettinger sold 12,240 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the transaction, the chief operating officer now owns 87,706 shares in the company, valued at $6,577,950. The trade was a 12.25 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.